Longport wins first LDS order

Article

Ultrasound developer Longport of Swarthmore, PA, has received its first commercial order for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). The

Ultrasound developer Longport of Swarthmore, PA, has received its first commercial order for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). The order is for 25 of the systems, and comes from UltraScan East of Allentown, PA.

The order is the latest good news for the company. In April, Longport signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longport’s R&D efforts (SCAN 5/26/99). The firm then received clearance for LDS from the Food and Drug Administration in June. In September, Longport formed an international subsidiary to begin worldwide marketing of LDS, and applied for listing on the Pacific Stock Exchange.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.